Raras
Buscar doenças, sintomas, genes...
Doença veno-oclusiva hepática
ORPHA:890CID-10 · K76.5CID-11 · DB98.6DOENÇA RARA

A doença veno-oclusiva hepática (DVO hepática) é uma condição resultante de lesão tóxica nos capilares sinusoidais hepáticos que leva à obstrução das pequenas veias hepáticas.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A doença veno-oclusiva hepática (DVO hepática) é uma condição resultante de lesão tóxica nos capilares sinusoidais hepáticos que leva à obstrução das pequenas veias hepáticas.

Pesquisas ativas
3 ensaios
25 total registrados no ClinicalTrials.gov
Publicações científicas
754 artigos
Último publicado: 2026 Feb
Medicamentos
2 registrados
DEFIBROTIDE SODIUM, DALTEPARIN SODIUM

Tem tratamento?

2 medicamentos registrados
Ver detalhes, fases e interações →
DEFIBROTIDE SODIUMDALTEPARIN SODIUM

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: K76.5
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫃
Digestivo
8 sintomas
🩸
Sangue
7 sintomas
🫁
Pulmão
6 sintomas
🛡️
Imunológico
3 sintomas
🧠
Neurológico
3 sintomas
🫘
Rins
2 sintomas

+ 16 sintomas em outras categorias

Características mais comuns

90%prev.
Insuficiência renal
Muito frequente (99-80%)
90%prev.
Icterícia
Muito frequente (99-80%)
90%prev.
Ascite
Muito frequente (99-80%)
90%prev.
Aumento da bilirrubina total
Muito frequente (99-80%)
90%prev.
Hepatomegalia
Muito frequente (99-80%)
90%prev.
Insuficiência respiratória
Muito frequente (99-80%)
51sintomas
Muito frequente (9)
Frequente (2)
Muito raro (1)
Sem dados (39)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 51 características clínicas mais associadas, ordenadas por frequência.

Insuficiência renalRenal insufficiency
Muito frequente (99-80%)90%
IcteríciaJaundice
Muito frequente (99-80%)90%
AsciteAscites
Muito frequente (99-80%)90%
Aumento da bilirrubina totalIncreased total bilirubin
Muito frequente (99-80%)90%
HepatomegaliaHepatomegaly
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico754PubMed
Últimos 10 anos200publicações
Pico202461 papers
Linha do tempo
2026Hoje · 2026🧪 2000Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Not applicable.

SP110Sp110 nuclear body proteinDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Transcription factor. May be a nuclear hormone receptor coactivator. Enhances transcription of genes with retinoic acid response elements (RARE)

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Hepatic venoocclusive disease with immunodeficiency

Autosomal recessive primary immunodeficiency associated with hepatic vascular occlusion and fibrosis. The immunodeficiency is characterized by severe hypogammaglobulinemia, combined T and B-cell immunodeficiency, absent lymph node germinal centers, and absent tissue plasma cells.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
66.4 TPM
Sangue
41.0 TPM
Baço
35.3 TPM
Pulmão
19.7 TPM
Nervo tibial
18.0 TPM
OUTRAS DOENÇAS (2)
hepatic veno-occlusive disease-immunodeficiency syndromeMycobacterium tuberculosis, susceptibility
HGNC:5401UniProt:Q9HB58

Medicamentos e terapias

DEFIBROTIDE SODIUMPhase 4

Mecanismo: Plasminogen activator

DALTEPARIN SODIUMPhase 3

Mecanismo: Antithrombin-III activator

Ver mais no OpenTargets

Variantes genéticas (ClinVar)

97 variantes patogênicas registradas no ClinVar.

🧬 SP110: NM_080424.4(SP110):c.1447+1G>C ()
🧬 SP110: NM_080424.4(SP110):c.1448-2A>G ()
🧬 SP110: NM_080424.4(SP110):c.1359_1360del (p.Lys453_Ser454insTer) ()
🧬 SP110: NM_080424.4(SP110):c.708del (p.Asp237fs) ()
🧬 SP110: NM_080424.4(SP110):c.1493_1494insCAAC (p.Pro499fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 509 variantes classificadas pelo ClinVar.

51
102
356
Patogênica (10.0%)
VUS (20.0%)
Benigna (69.9%)
VARIANTES MAIS SIGNIFICATIVAS
SP110: NM_080424.4(SP110):c.1447+1G>C [Likely pathogenic]
SP110: NM_080424.4(SP110):c.1448-2A>G [Likely pathogenic]
SP110: NM_080424.4(SP110):c.1901G>A (p.Gly634Asp) [Uncertain significance]
SP110: NM_080424.4(SP110):c.28G>A (p.Glu10Lys) [Uncertain significance]
SP110: NM_080424.4(SP110):c.166A>G (p.Arg56Gly) [Uncertain significance]

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
Aprovado2
3Fase 35
2Fase 23
·Pré-clínico8
Medicamentos catalogadosEnsaios clínicos· 2 medicamentos · 16 ensaios
✓ Aprovados — podem ser usados hoje
DEFIBROTIDE SODIUM
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Doença veno-oclusiva hepática

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

25 ensaios clínicos encontrados, 3 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥇Melhor nível de evidência: Meta-análise
Timeline de publicações
229 papers (10 anos)
#1

Transjugular intrahepatic portosystemic shunt improves survival in anticoagulation-resistant hepatic sinusoidal obstructive syndrome patients: A multicenter retrospective study.

World journal of hepatology2026 Feb 27

Anticoagulation therapy is recommended during the acute or subacute stage for patients with pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome (PA-HSOS). Transjugular intrahepatic portosystemic shunts (TIPS) is suggested as a step-up treatment when patients do not respond to anticoagulants. However, more evidence of the efficacy of TIPS is needed. To evaluate the effect of TIPS in these patients. Between January 2013 and September 2020, we retrospectively enrolled patients with PA-HSOS who did not respond to short-term anticoagulation therapy at four hospitals. The patients were divided into a TIPS treatment group and an anticoagulation therapy group. Baseline information and clinical characteristics were collected and recorded. Survival in both groups was the primary study endpoint and the risk factors for patient death were further analyzed. A total of 99 patients were enrolled according to the inclusion and exclusion criteria (63 in the TIPS group and 36 in the anticoagulation therapy group). There were 17 deaths during the median follow-up time of 32.5 months. Treatment, age, aspartate aminotransferase, and serum total bilirubin were independent risk factors for predicting death. The survival of patients in the TIPS group was significantly greater than that of patients in the continuing anticoagulation therapy group (P = 0.028). When stratified by the Drum-Tower Severity Scoring, in the TIPS group, mild and moderate patients had better outcomes than severe patients. TIPS can improve the transplant-free survival rate in patients with PA-HSOS who do not respond to short-term anticoagulation therapy, and patients with mild and moderate Drum-Tower Severity Scoring grade can benefit from TIPS.

#2

Epidemiology and Outcomes of Hepatic Veno-Occlusive Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Descriptive Analysis of the U.S. National Inpatient Sample.

Hematology/oncology and stem cell therapy2026 Feb 02

Hepatic veno-occlusive disease (HVOD), or sinusoidal obstruction syndrome (SOS), is a potentially liefe-threatening complication following allogeneic stem cell transplantation (allo-SCT). Historically, HVOD has affected up to 60% of allo-SCT recipients, with reported mortality rates exceeding 75% in severe cases. The approval of defibrotide in 2016 represented a major therapeutic milestone, significantly improving outcomes in high-risk patients. Despite this advancement, large-scale data on HVOD epidemiology & outcomes in allo-SCT recipients remain limited. This study aims to address these gaps & offer updated insights into its clinical impact. We utilized National Inpatient Sample (2016-2020) to examine factors associated with HVOD in allo-SCT recipients. Admissions for allo-SCT & HVOD were identified using International Classification of Diseases, Tenth Revision. Baseline characteristics, including patient demographics, hospital characteristics, comorbidities, complications & outcomes were compared between allo-SCT admissions with & without HVOD. Categorical variables were analyzed by χ² test (%), & continuous variables by adjusted Wald's test (mean±SD). During the study period, 200 allo-SCT admissions with HVOD were identified. HVOD admissions were younger (45.05 vs. 52.42 years; P=0.0045) & were more likely to be female (43.72% vs. 25%; P=0.0191). They had higher rates of acute graft-versus-host disease (GVHD) (17.5% vs. 6.47%; P=0.0043), acute respiratory failure (32.5% vs. 8.37%; P<0.001), & acute kidney injury (50% vs. 20.66%; P<0.001). Hepatic complications, including portal hypertension (7.5% vs. 0.52%; P<0.001), hepatic encephalopathy (12.5% vs. 0.28%; P<0.001), cirrhosis (7.5% vs. 0.07%; P<0.001), ascites (37.5% vs. 1.97%; P<0.001) & spontaneous bacterial peritonitis (2.5% vs. 0.06%; P<0.001) were also more common in this cohort. HVOD was associated with worse outcomes, including longer hospital stays (45.5 vs. 29.51 days; P<0.001) & over 6 times higher in-hospital mortality (30% vs. 4.72%; P<0.001). HVOD also imposed a greater economic burden, with more than double mean total hospitalization charges ($1,321,650 vs. $541,391.1; P<0.001) & nearly triple hospitalization costs ($358,463.2 vs. $141,464.1; P<0.001). This study describes HVOD-specific characteristics in allo-SCT admissions. Patients with HVOD were younger, had higher comorbidity burden, & showed increased rates of acute GVHD, multiorgan dysfunction, & hepatic complications. They also faced high in-hospital mortality, longer hospital stays, & greater healthcare costs.

#3

Two Cases of Hepatic Epithelioid Hemangioendothelioma Misdiagnosed With Hepatic Veno-Occlusive Disease.

Case reports in hepatology2026

Hepatic epithelioid hemangioendothelioma (HEHE) is a rare tumor of vascular origin with an incidence of < 0.1/100,000. The disease is easily misdiagnosed. The aim of this article is to increase public awareness and vigilance of HEHE. We report two cases presenting with fever, abdominal discomfort, abnormal liver function, and jaundice. Computed tomography (CT) and magnetic resonance imaging (MRI) of the abdomen suggested hepatic stasis, venous compression, and ascites, and liver biopsy was initially misdiagnosed as hepatic veno-occlusive disease (VOD), which did not improve with treatment. In the first case, a male patient, after liver transplantation, pathological and immunohistochemical (IHC) analyses revealed hyperplasia of blood vessels in the liver tissue with dilated lumen and heterogeneous cells. Immunohistochemistry was performed and showed CD34 positivity, confirming the diagnosis of HEHE. The second female patient had liver bruising and ascites on imaging, and the first hepatic puncture was reported to be VOD, which did not improve with treatment. Repeat hepatic puncture was performed, and the diagnosis of HEHE was confirmed after a second repathology with additional immunohistochemistry for HEHE. These misdiagnosis cases highlight the challenge of diagnosing HEHE. This is the first report of misdiagnosis of HEHE as VOD. This article analyzes the underlying causes of misdiagnosis of HEHE and emphasizes the causes of imaging misdiagnosis and the importance of repeated hepatic puncture biopsy and immunohistochemistry in the diagnosis of HEHE.

#4

Real-World Outcome of Defibrotide Treatment for Severe Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.

Transplantation and cellular therapy2026 Feb

Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication following hematopoietic cell transplantation (HCT), with a markedly poor prognosis in patients with severe or very severe presentations. Defibrotide (DF) is the sole approved treatment for severe to very severe VOD/SOS, but real-world evidence remains limited, particularly in East Asian populations. We retrospectively analyzed 73 adult patients with severe or very severe VOD/SOS treated with DF between 2016 and 2023 at a single tertiary center in Korea. Diagnosis and grading were based on the revised European Society for Blood and Marrow Transplantation criteria. During the study period, national reimbursement guidelines for DF evolved from requiring ≥4 of 6 severity criteria to ≥2 of 5 severity criteria, allowing earlier initiation of treatment. The median time from HCT to diagnosis of VOD/SOS was 24 days (range, 1 to 843 days), and DF was administered within a median of 1 day after diagnosis. At DF initiation, 40 patients were classified as severe and 33 were classified as very severe; disease progression resulted in 53 patients reaching the very severe category. The overall response rate was 46.5%, and complete resolution was achieved in 39.7% of cases. The 100-day overall survival was 34.2%, significantly higher in the patients receiving DF within 2 days of diagnosis (36.0% versus 17.4%; P = .049). High total bilirubin levels at diagnosis and at the worst disease period were strongly associated with poor long-term survival regardless of severity criteria. These data provide real-world support for the early use of DF and suggest the prognostic utility of total bilirubin level in guiding treatment for VOD/SOS following HCT.

#5

Impact of Oral Eicosapentaenoic Acid on Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Onset Prevention: Single-Center Retrospective Analysis.

Transplantation and cellular therapy2026 Mar

Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a serious complication associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). Although ursodeoxycholic acid and defibrotide can reduce the risk of VOD/SOS, preventive efforts remain insufficient. In 2009, we began prescribing oral eicosapentaenoic acid (EPA) to mitigate post-transplant complications. Notably, no patients receiving EPA developed VOD/SOS. In this retrospective study, we analyzed 138 transplants from 123 patients who underwent allo-HSCT at Ehime University Hospital between April 2008 and June 2024. Ninety-one patients received EPA after allo-HSCT (EPA group), while 47 patients did not (no-EPA group). EPA was administered at a dose of 1800 mg/d, divided into 2 or 3 doses. All patients were taking ursodeoxycholic acid. VOD/SOS occurred in 3 patients in the no-EPA group (6.5%) and in none of the EPA group (P = 0.014). Early post-transplant mortality within 100 d did not differ significantly between groups. Although causal inference is limited by the retrospective design of the study, our findings suggest that EPA use may be associated with a lower incidence of VOD/SOS. These findings warrant prospective, multicenter trials to determine whether EPA can improve transplant outcomes by reducing the incidence of VOD/SOS.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC361 artigos no totalmostrando 198

2026

[Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Very Early-Onset Inflammatory Bowel Disease Caused by IL-10RA Mutation].

Zhongguo shi yan xue ye xue za zhi
2026

Transjugular intrahepatic portosystemic shunt improves survival in anticoagulation-resistant hepatic sinusoidal obstructive syndrome patients: A multicenter retrospective study.

World journal of hepatology
2026

Hepatic Sinusoidal Obstruction Syndrome Induced by Pyrrolizidine Alkaloids from Gynura segetum: Mechanisms and Therapeutic Advances.

Molecules (Basel, Switzerland)
2026

Gancao decoction ameliorated senecionine-induced Hepatic Sinusoidal Obstruction Syndrome in mice by inhibiting NET formation and senecionine bioactivation in liver.

Journal of ethnopharmacology
2026

Epidemiology and Outcomes of Hepatic Veno-Occlusive Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Descriptive Analysis of the U.S. National Inpatient Sample.

Hematology/oncology and stem cell therapy
2026

Two Cases of Hepatic Epithelioid Hemangioendothelioma Misdiagnosed With Hepatic Veno-Occlusive Disease.

Case reports in hepatology
2026

Chronic portal hypertension following inotuzumab ozogamicin in a low-risk patient: a case of overriding baseline risk and long-term management.

Annals of hematology
2025

[Research progress on animal models relevant to porto-sinusoidal vascular disease].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
2025

Proteomic Signatures and Early Biomarkers Predicting Veno-Occlusive Disease in Pediatric Patients Undergoing Haploidentical Hematopoietic Cell Transplantation with Busulfan-Based Conditioning and Post-Transplant Cyclophosphamide.

Transplantation and cellular therapy
2025

Real-world treatment outcome and toxicity analysis of inotuzumab ozogamicin in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: multicenter prospective observational study.

Therapeutic advances in hematology
2026

Effects of glutathione- S -transferase polymorphisms on intravenous busulfan in hematopoietic stem cell transplant patients: a meta-analysis.

Pharmacogenetics and genomics
2025

Transjugular intrahepatic portosystemic shunt for hepatic sinusoidal obstruction syndrome with primary biliary cholangitis and alcoholic liver disease: a case report.

Frontiers in medicine
2025

[Inotuzumab ozogamicin-associated sinusoidal obstruction syndrome/veno-occlusive disease diagnosed by transjugular liver biopsy].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2025

Modeling antithymocyte globulin-induced microvasculopathy using human iPSC-derived vascularized liver organoids.

Cell reports. Medicine
2025

Non-caucasian ethnicity as a risk factor for sinusoidal obstruction syndrome/hepatic veno-occlusive disease following haematopoietic stem cell transplantation.

Anales de pediatria
2025

Community perceptions and practices on hepatic veno-occlusive disease in Tigray, Ethiopia: An explorative study challenging the attribution to Ageratum conyzoides.

PLoS neglected tropical diseases
2026

Real-World Outcome of Defibrotide Treatment for Severe Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.

Transplantation and cellular therapy
2026

Impact of Oral Eicosapentaenoic Acid on Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Onset Prevention: Single-Center Retrospective Analysis.

Transplantation and cellular therapy
2025

Efficacy of ibrutinib and diagnostic liver biopsy for idiopathic refractory ascites after allogeneic stem cell transplantation.

International journal of hematology
2025

Prognostic Impact of the Level of Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation on Pediatric Patients With Acute Lymphoblastic Leukemia: A 10-Year Single-Center Study.

Clinical lymphoma, myeloma &amp; leukemia
2025

Veno-Occlusive Disease in Very Young Children: A Profile of High Morbidity With Low Mortality.

Pediatric blood &amp; cancer
2025

Multiple Hematopoietic Stem Cell Transplantations in Pediatric Acute Myeloid Leukemia: Prognostic Significance of Remission and Severe Sinusoidal Obstruction Syndrome.

Pediatric blood &amp; cancer
2025

Transient and Shear-Wave Elastography in the Detection of Hepatic Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Transplantation and cellular therapy
2025

Serum ascites albumin gradient in predicting the severity of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids.

Clinical and experimental hepatology
2025

Efficacy and safety of transjugular intrahepatic portosystemic shunt in hepatic sinusoidal obstruction syndrome: systematic review and meta-analysis.

Frontiers in medicine
2025

Syndecan-1 is Associated With Sinusoidal Obstruction Syndrome and Severe Acute Graft-Versus-Host Disease After Pediatric Hematopoietic Stem Cell Transplantation.

Pediatric blood &amp; cancer
2025

Albumin-Bilirubin and Severity as Key Factors of Recovery in Patients With PA-HSOS Undergoing Transjugular Intrahepatic Portosystemic Shunt.

Annali italiani di chirurgia
2025

Antibody-mediated rejection without elevated anti-blood type antibody after ABO-incompatible living donor liver transplantation: a case report.

Clinical journal of gastroenterology
2025

Genetic Susceptibility in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease: A Case-Control Study.

International journal of molecular sciences
2025

Defibrotide for Protecting Against and Managing Endothelial Injury in Hematologic Malignancies and COVID-19.

Biomolecules
2025

Drug-induced sinusoidal obstruction syndrome: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System (FEARS).

BMC pharmacology &amp; toxicology
2025

Vascular Liver Disease: Emerging Concepts in the Sinusoidal Space.

Clinics in liver disease
2025

Hepatotoxicity of Chemotherapy and Immune Checkpoint Inhibitors.

Clinics in liver disease
2025

The Liver in Hematologic Malignancies: Lymphoma, Leukemia, and Myeloma.

Clinics in liver disease
2025

Results of a Phase II Trial for Intermediate-Risk Rhabdomyosarcoma Treatment Protocol JRS-I: A Report From the Japan Rhabdomyosarcoma Study Group.

Pediatric blood &amp; cancer
2025

Unveiling the clinical spectrum of Porto-Sinusoidal Vascular Disorder (PSVD) with chronic HBV infection: insights from a retrospective Chinese cohort.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2026

PU.1 aggravates hepatic sinusoidal obstruction syndrome by upregulating PTBP1 and activating the Wnt/β-catenin pathway.

Histology and histopathology
2025

Utility of tolvaptan sodium phosphate for refractory fluid retention in post-transplant sinusoidal obstruction syndrome.

International journal of hematology
2025

Platelet aggregation elicits FasL expression and hepatocyte apoptosis in sinusoidal obstruction syndrome.

Scientific reports
2025

Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide.

Transplantation and cellular therapy
2025

Classical and Late-Onset SOS/VOD After Allogeneic HSCT: A Japanese Transplant Registry Analysis.

American journal of hematology
2025

Validation of Drum Tower Severity Scoring (DTSS) System for Pyrrolizidine Alkaloid-Induced Hepatic Sinusoidal Obstruction Syndrome.

Journal of digestive diseases
2025

Hepatic sinusoidal congestion associated with inotuzumab therapy in patients with B-cell acute lymphoblastic leukemia, a proposal for a new clinical entity: Calicheamicin syndrome.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
2025

Ultrasonographic scoring system for SOS/VOD in pediatric hematopoietic stem cell transplant recipients.

International journal of hematology
2025

Management of liver sinusoidal obstruction syndrome/veno-occlusive disease in adults: a 2025 perspective from an international expert group.

Bone marrow transplantation
2025

Atypical features of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after inotuzumab ozogamicin in adult patients with acute lymphoblastic leukemia.

Blood research
2025

Diagnostic accuracy of liver stiffness measurement for the diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome after hematopoietic stem cell transplantation (HSCT), the ELASTOVOD STUDY: an investigator-initiated, prospective, multicentre diagnostic clinical trial.

Bone marrow transplantation
2025

S-Adenosylmethionine Inhibits Plasminogen-Activating Inhibitor-1 and Protects Male Mice From FOLFOX-Induced Liver Injury.

Cellular and molecular gastroenterology and hepatology
2025

Operational procedure sharing pathway in veno-occlusive disease: a Delphi consensus-based recommendations.

Frontiers in oncology
2025

Soluble Thrombomodulin Is Associated With Endothelial Dysfunction Syndromes After Pediatric Hematopoietic Stem Cell Transplantation.

Pediatric blood &amp; cancer
2025

CIBMTR Registry Data on Inotuzumab Ozogamicin Treatment in Patients with ALL Who Proceeded to Hematopoietic Stem Cell Transplant-A Podcast.

Targeted oncology
2025

Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2/HO1 and NF-κB Pathway.

Liver international : official journal of the International Association for the Study of the Liver
2025

Complement activation and vascular complications after pediatric allogeneic hematopoietic stem cell transplantation.

Scientific reports
2025

[A case report of gastric cancer combined with hepatic sinusoidal obstruction syndrome].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
2025

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study.

Haematologica
2025

Pretransplant Minimal Pleural and Peritoneal Effusion Is a Potential Poor Prognostic Indicator in Allogeneic Hematopoietic Stem Cell Transplantation.

Clinical transplantation
2025

A case of late-onset sinusoidal obstruction syndrome diagnosed histologically before meeting diagnostic criteria.

International journal of hematology
2025

Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives.

Archives of toxicology
2025

A Two-Center Study of a Prognostic Model Related to Acute Kidney Injury After Allogeneic Hematopoietic Stem Cell Transplantation in Children: Development of a New Predictive Dynamic Nomogram.

Pediatric blood &amp; cancer
2024

Perioperative outcomes of sinusoidal obstruction syndrome in patients undergoing liver resection for colorectal metastases after neoadjuvant chemotherapy: a retrospective cohort research.

Annals of surgical treatment and research
2025

The EASIX score as a predictor of sinusoidal obstruction syndrome and nonrelapse mortality in paediatric patients receiving allogeneic haematopoietic stem cell transplantation.

Bone marrow transplantation
2025

Continuous Kidney Replacement Therapy in Children With Sinusoidal Obstruction Syndrome After Hematopoietic Cell Transplant: Outcome and Liberation.

Pediatric blood &amp; cancer
2024

Burden of illness of non-hematopoietic stem cell transplant-related hepatic sinusoidal obstruction syndrome: A systematic review.

Heliyon
2024

Prognostic Factors Associated With Increased Mortality in Pediatric Veno-Occlusive Disease Following Hematopoietic Cell Transplantation.

Clinical transplantation
2024

Potential therapeutic uses of L-citrulline beyond genetic urea cycle disorders.

Journal of inherited metabolic disease
2025

Porto-sinusoidal vascular disorder with known etiologies had more severe portal hypertension and poorer outcomes.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2025

[Rifaximin curative effect and mechanism on monocrotaline-induced hepatic sinusoidal obstruction syndrome in mice].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
2025

The benefits of prophylactic defibrotide: Are the tides turning?

Pediatric blood &amp; cancer
2024

[Clinical analysis of allogeneic hematopoietic cell transplantation in 9 patients with hematological malignancies complicated by Gilbert's syndrome].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2025

An international survey to better understand the current incidence, severity, and management of VOD/SOS.

Bone marrow transplantation
2024

[Sinusoidal obstruction syndrome/veno-occlusive disease: a complication to overcome].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2024

Hepatic sinusoidal obstruction syndrome after immune-checkpoint-inhibitor therapy: when the liver sends SOS.

BMJ case reports
2024

Early defibrotide therapy and risk factors for post-transplant veno-occlusive disease/sinusoidal obstruction syndrome in childhood.

Pediatric blood &amp; cancer
2024

Risk Factors for Sinusoidal Obstruction Syndrome After Hematopoietic Stem Cell Transplantation in Children and Young Adults: A Systematic Review and Meta-Analysis.

Clinical transplantation
2024

[Application Values of New Ultrasound Technologies in the Diagnosis of Hepatic Sinusoidal Obstruction Syndrome].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
2024

Biomarker-derived fast-and-frugal decision tree for preemption of veno-occlusive disease/sinusoidal obstructive syndrome.

Blood advances
2024

Hepatic veno-occlusive disease with asparaginase products: a review of cases reported to the FDA adverse event reporting system and published in the literature.

Pediatric hematology and oncology
2024

Refractory Thrombocytopenia is the Earliest Diagnostic Criterion for Sinusoidal Obstruction Syndrome in Children.

Journal of pediatric hematology/oncology
2025

Intrinsic Causes of Nonfibrotic Portal Hypertension-A Clinicopathologic Review of 56 Patients.

International journal of surgical pathology
2024

Hepatic Sinusoidal Disorders.

Radiographics : a review publication of the Radiological Society of North America, Inc
2024

Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin.

Blood cancer journal
2024

Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.

Cancer
2024

ANZTCT practice statement: sinusoidal obstruction syndrome/veno-occlusive disease diagnosis and management.

Internal medicine journal
2024

Hepatic Veno-Occlusive Disease and Colorectal Cancer: Expect the Unexpected.

Life (Basel, Switzerland)
2024

A rare case of Gynura-segetum-related hepatic sinus obstruction syndrome complicated with alcoholic liver disease.

JPMA. The Journal of the Pakistan Medical Association
2024

[Porto sinusoidal vascular disease: an unusual cause of digestive bleeding].

Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru
2024

Gut microbiota promotes macrophage M1 polarization in hepatic sinusoidal obstruction syndrome via regulating intestinal barrier function mediated by butyrate.

Gut microbes
2024

Hemostasis and complement in allogeneic hematopoietic stem cell transplantation: clinical significance of two interactive systems.

Bone marrow transplantation
2024

Verification of the Prediction Accuracy of a Biomarker-Based Prognostic for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Hematopoietic Cell Transplantation (HCT).

Transplantation and cellular therapy
2024

Incidence, Etiology and Prognosis of Initial Liver Injury After Allogeneic Hematopoietic Stem Cell Transplantation: A Multi-Center Retrospective Study.

Transplantation proceedings
2024

Porto-sinusoidal Vascular Disease and Portal Hypertension.

Clinics in liver disease
2024

Tacrolimus-Induced Hepatic Vein Occlusive Disease After Deceased Donor Liver Transplantation: A Case Report.

Transplantation proceedings
2024

Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular Therapy Group (GETH).

Transplantation and cellular therapy
2024

Review of imaging findings in hepatic veno-occlusive disease.

European journal of radiology
2024

Veno-Occlusive Disease: A Life-saving Novel Approach With Plasma Exchange, IVIG, and Steroid, Without Defibrotide.

Journal of pediatric hematology/oncology
2024

Sepsis and pneumonia caused by Enterococcus faecium following liver transplantation treated with contezolid as the first-line therapy.

Journal of global antimicrobial resistance
2024

6-Mercaptopurine-associated Sinusoidal Obstructive Syndrome During Interim Maintenance I: A Case Report.

Journal of pediatric hematology/oncology
2024

Shear wave elastography and dispersion imaging for hepatic veno-occlusive disease prediction after pediatric hematopoietic stem cell transplantation: a feasibility study.

Pediatric radiology
2024

Functional metabolomics characterizes the contribution of farnesoid X receptor in pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.

Archives of toxicology
2024

Liver stiffness measurements predict Sinusoidal Obstructive Syndrome after hematopoietic stem cell transplantation.

Bone marrow transplantation
2024

Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols.

Transplantation and cellular therapy
2024

[Role of liver sinusoidal endothelial cell damage in the developmental process of hepatic sinusoidal obstruction syndrome: a focus on the research progress of immune inflammatory mechanisms].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
2024

Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.

Transplantation and cellular therapy
2024

Hepatic veno-occlusive disease complicated with extreme hyperammonaemia (920 µmol/L) treated with defibrotide, lactulose, rifampin and haemodialysis.

BMJ case reports
2024

Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation.

Annals of hematology
2024

Gynura segetum induces hepatic sinusoidal obstruction syndrome in a child: A case report.

Medicine
2024

Clinical features and risk factors of hepatic sinusoidal obstruction syndrome in children after hematopoietic stem cell transplantation: A single-center experience.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
2024

Bile cast nephropathy after sinusoidal obstruction syndrome.

Kidney international
2024

Incidence, management and outcome of Hepatic Veno-Occlusive disease /Sinusoidal Obstruction Syndrome after hematopoietic stem cell transplant in Thalassemia major patients: A prospective study of Pakistani BMT.

Pakistan journal of medical sciences
2024

Cilostazol improves the prognosis after hepatectomy in rats with sinusoidal obstruction syndrome.

Journal of gastroenterology and hepatology
2024

Anticoagulant therapy likely increases risk of bleeding in Gynura segetum-induced hepatic sinus obstruction syndrome.

Medicine
2024

Evaluation of Busulfan as a Third-Party Immunoassay on a Clinical Chemistry Analyzer.

The journal of applied laboratory medicine
2024

Multiplex Proteomics in the Identification of Potential Biomarkers of Very Severe Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease in Allogeneic Hematopoietic Cell Transplant Patients Treated with Defibrotide.

Acta haematologica
2024

Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease.

Bone marrow transplantation
2024

Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation.

Blood advances
2025

Azathioprine-induced Veno-occlusive Hepatotoxicity in a Patient with Myasthenia Gravis.

Current drug safety
2024

Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review.

Biomedicines
2025

Dissociation in hepatic vein pressure gradient, liver stiffness measurement and complications in histological subtypes of porto-sinusoidal vascular disease.

Journal of clinical pathology
2024

Analysis of laboratory parameters before the occurrence of hepatic sinusoidal obstruction syndrome in children, adolescents, and young adults after hematopoietic stem cell transplantation.

Journal of cancer research and clinical oncology
2023

[Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2024

Histological evaluation of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: Correlation with Drum Tower Severity Scoring.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
2024

Utility of liver stiffness measurement in the diagnosis of sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic stem cell transplantation.

Journal of medical ultrasonics (2001)
2024

Clinical outcomes of early defibrotide discontinuation: a single-center case series.

Bone marrow transplantation
2024

Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome/venous occlusive disease.

Haematologica
2024

Early-onset hepatic veno-occlusive disease after liver transplantation: an institutional experience and analysis of a literature-based cohort.

Surgery today
2024

Primary Budd-Chiari syndrome versus sinusoidal obstruction syndrome: a review.

Current medical research and opinion
2023

Assaying ADAMTS13 Activity as a Potential Prognostic Biomarker for Sinusoidal Obstruction Syndrome in Mice.

International journal of molecular sciences
2024

Prospective Assessment of Treatment-Induced Liver Injury as a Cause of Diffuse Pathologic Hepatic Enhancement in Contrast-Enhanced Ultrasound.

Ultrasound in medicine &amp; biology
2023

Rifaximin Prevents Intestinal Barrier Dysfunction and Alleviates Liver Injury in MCT-induced HSOS Mice.

Current medical science
2024

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.

Blood
2023

Constructing training set using distance between learnt graphical models of time series data on patient physiology, to predict disease scores.

PloS one
2024

Post-allogeneic Hematopoietic Stem Cell Transplantation Portal Hypertension Not Associated with Liver Cirrhosis, Veno-occlusive Disease, or Graft-versus-host Disease.

Internal medicine (Tokyo, Japan)
2023

HokUS-10 scoring system predicts the treatment outcome for sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation.

Scientific reports
2023

Andrographolide attenuated MCT-induced HSOS via regulating NRF2-initiated mitochondrial biogenesis and antioxidant response.

Cell biology and toxicology
2023

Rare variants in complement system genes associate with endothelial damage after pediatric allogeneic hematopoietic stem cell transplantation.

Frontiers in immunology
2023

Diagnosis of sinusoidal obstruction syndrome: can biopsy be the key?

Annals of hematology
2023

[Evaluation of the efficacy of TIPS in 27 patients with hepatic sinus obstruction syndrome in the near and medium term].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
2023

Transjugular Intrahepatic Portosystemic Shunt is effective to treat portal hypertension due to sinusoidal obstructive syndrome.

Clinics and research in hepatology and gastroenterology
2023

Busulfan-induced hepatic sinusoidal endothelial cell injury: Modulatory role of pirfenidone for therapeutic purposes.

Toxicology in vitro : an international journal published in association with BIBRA
2023

Current incidence, severity, and management of veno-occlusive disease/sinusoidal obstruction syndrome in adult allogeneic HSCT recipients: an EBMT Transplant Complications Working Party study.

Bone marrow transplantation
2023

Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids.

Medicine
2023

Retrospective study of risk factors for pericardial effusion after haematopoietic stem cell transplantation in children.

Hematology (Amsterdam, Netherlands)
2023

Liver Pathology After Hematopoietic Stem Cell Transplantation.

Surgical pathology clinics
2023

Concordance between HokUS-10 Scoring and Transjugular Liver Biopsy for the Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Allogeneic Stem Cell Transplantation.

Transplantation and cellular therapy
2023

[Posttransplant complications: GVHD and SOS/VOD].

[Rinsho ketsueki] The Japanese journal of clinical hematology
2023

Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome - Authors' reply.

The Lancet. Haematology
2023

Defibrotide prophylaxis for prevention of sinusoidal obstruction syndrome.

The Lancet. Haematology
2023

Assessment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome using different scanning approaches for the ultrasonographic evaluation of portal vein blood flow and hepatic artery resistive index in hematopoietic stem cell transplant recipients.

Journal of medical ultrasonics (2001)
2023

A phase 2 trial of defibrotide for the prevention of chimeric antigen receptor T-cell-associated neurotoxicity syndrome.

Blood advances
2023

Transjugular intrahepatic portosystemic shunt for pyrrolidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective cohort study.

European journal of gastroenterology &amp; hepatology
2023

Point shear-wave elastography for the diagnosis of veno-occlusive disease in children and young adults.

Pediatric radiology
2023

Peritoneal and Pleural Drains in Pediatric Hematopoietic Cell Transplant Recipients with Veno-Occlusive Disease are Safe and Do Not Adversely Impact Clinical Outcomes.

Hematology/oncology and stem cell therapy
2023

Melatonin attenuates monocrotaline-induced hepatic sinusoidal obstruction syndrome in rats via activation of Sirtuin-3.

Journal of biochemical and molecular toxicology
2023

Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: a never-ending story and no easy answer.

Bone marrow transplantation
2023

Transjugular Intrahepatic Portosystemic Shunt Benefits for Hepatic Sinusoidal Obstruction Syndrome Associated with Consumption of Gynura Segetum: a Propensity Score-Matched Analysis.

Cardiovascular and interventional radiology
2023

Sinusoidal obstruction syndrome associated with disseminated toxoplasmosis involving the liver after allogeneic hematopoietic stem cell transplantation: A case report.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
2023

Thymosin β4 Exerts a Cytoprotective Function and Attenuates Liver Injury in Murine Hepatic Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation.

Transplantation and cellular therapy
2023

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial.

The Lancet. Haematology
2023

Sinusoidal Obstruction Syndrome (SOS) and Defibrotide: We Are Not There Yet.

Transplantation and cellular therapy
2023

The Role of the Transjugular Intrahepatic Porto-Systemic Shunt in an Emergency Setting.

Life (Basel, Switzerland)
2023

Low Plasma Levels of Hyaluronic Acid Might Rule Out Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation.

Disease markers
2023

Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT).

Bone marrow transplantation
2023

Hypofibrinolysis in pediatric patients with veno-occlusive disease in hematopoietic stem cell transplantation.

Journal of cancer research and clinical oncology
2023

Prospective assessment of risk biomarkers of sinusoidal obstruction syndrome after hematopoietic cell transplantation.

JCI insight
2023

A novel integrative multi-omics approach to unravel the genetic determinants of rare diseases with application in sinusoidal obstruction syndrome.

PloS one
2023

Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?

The Lancet. Haematology
2023

Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.

The Lancet. Haematology
2023

Molecular Advances in Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease.

International journal of molecular sciences
2023

Usefulness of two-dimensional shear wave elastography in diagnosing hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplantation.

Ultrasonography (Seoul, Korea)
2023

Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study.

Transplantation and cellular therapy
2022

[Research progress of hepatic sinusoidal obstruction syndrome].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
2023

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia.

Therapeutic advances in hematology
2023

Biomarkers for early complications post hematopoietic cell transplantation: Insights and challenges.

Frontiers in immunology
2023

Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin.

Leukemia &amp; lymphoma
2023

Risk assessment of short-term intake of pyrrolizidine alkaloids in food: derivation of an acute reference dose.

Food additives &amp; contaminants. Part A, Chemistry, analysis, control, exposure &amp; risk assessment
2022

[A Case of Sinusoidal Obstruction Syndrome and Nodular Regenerative Hyperplasia after Using Oxaliplatin for Rectal Cancer].

Gan to kagaku ryoho. Cancer &amp; chemotherapy
2023

Mid- to long-term outcomes of initial transjugular intrahepatic portosystemic shunt versus anticoagulation for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome.

European journal of gastroenterology &amp; hepatology
2023

Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.

Transplantation and cellular therapy
2023

Hepatobiliary disease after bone marrow transplant.

Expert review of gastroenterology &amp; hepatology
2022

Differential Diagnosis of Hyperferritinemia in Critically Ill Patients.

Journal of clinical medicine
2023

Interprofessional Team-based Care of the Hematopoietic Cell Transplantation Patient With Hepatic Veno-occlusive Disease/Sinusoidal Obstruction Syndrome.

Journal of pediatric hematology/oncology
2023

Transjugular Intrahepatic Portosystemic Shunt in Liver Transplant Recipients: Outcomes in Six Adult Patients.

Vascular and endovascular surgery
2023

Predictive factors of collateral vessel development induced by oxaliplatin-based chemotherapy.

International journal of clinical oncology
2023

Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.

Transplantation and cellular therapy
2023

Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.

Bone marrow transplantation
2022

Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome.

BMC gastroenterology
2022

Effects of bicyclol on hepatic sinusoidal obstruction syndrome induced by Gynura segetum.

Journal of clinical laboratory analysis
2022

Plugged percutaneous liver biopsy using Tru-cut needle and coils: A retrospective study.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
2023

Hepatic veno-occlusive disease accompanied by thrombotic microangiopathy developed during treatment of juvenile dermatomyositis and macrophage activation syndrome: A case report.

Modern rheumatology case reports
2023

Enoxaparin attenuates pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome by inhibiting oncostatin M expression.

Liver international : official journal of the International Association for the Study of the Liver
2022

Systematic screening and focused evaluation for veno-occlusive disease/sinusoidal obstructive syndrome (VOD/SOS) following allogeneic stem cell transplant is associated with earlier diagnosis and prompt institution of defibrotide treatment.

Frontiers in transplantation
2022

Ultrasonographic monitoring of sinusoidal obstruction syndrome in patients treated with inotuzumab ozogamicin.

International journal of hematology
2022

[Risk factors for acute kidney injury after hematopoietic stem cell transplantation in children: a retrospective study].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
2022

Model establishment and microarray analysis of mice with oxaliplatin‑induced hepatic sinusoidal obstruction syndrome.

Molecular medicine reports
2022

A Retrospective Cohort Study of the Efficacy, Safety, and Clinical Value of 6-TG versus 6-MP Maintenance Therapy in Children with Acute Lymphoblastic Leukemia.

BioMed research international
2022

Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.

International journal of clinical oncology
2023

Sinusoidal Obstruction Syndrome of the Liver Associated With 6-Mercaptopurine During Maintenance in a Child With T-cell Acute Lymphoblastic Leukemia.

Journal of pediatric hematology/oncology
2023

Mini-hyper CVD + CRIB (condensed rituximab, inotuzumab ozogamicin, and blinatumomab) for refractory pediatric B-acute lymphoblastic leukemia.

Pediatric blood &amp; cancer
Ver todos os 361 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Doença veno-oclusiva hepática.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Doença veno-oclusiva hepática

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Transjugular intrahepatic portosystemic shunt improves survival in anticoagulation-resistant hepatic sinusoidal obstructive syndrome patients: A multicenter retrospective study.
    World journal of hepatology· 2026· PMID 41809477mais citado
  2. Epidemiology and Outcomes of Hepatic Veno-Occlusive Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Descriptive Analysis of the U.S. National Inpatient Sample.
    Hematology/oncology and stem cell therapy· 2026· PMID 41630155mais citado
  3. Two Cases of Hepatic Epithelioid Hemangioendothelioma Misdiagnosed With Hepatic Veno-Occlusive Disease.
    Case reports in hepatology· 2026· PMID 41623667mais citado
  4. Real-World Outcome of Defibrotide Treatment for Severe Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation.
    Transplantation and cellular therapy· 2026· PMID 41086944mais citado
  5. Impact of Oral Eicosapentaenoic Acid on Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Onset Prevention: Single-Center Retrospective Analysis.
    Transplantation and cellular therapy· 2026· PMID 41057124mais citado
  6. [Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation for Very Early-Onset Inflammatory Bowel Disease Caused by IL-10RA Mutation].
    Zhongguo Shi Yan Xue Ye Xue Za Zhi· 2026· PMID 41846353recente
  7. Proteomic Signatures and Early Biomarkers Predicting Veno-Occlusive Disease in Pediatric Patients Undergoing Haploidentical Hematopoietic Cell Transplantation with Busulfan-Based Conditioning and Post-Transplant Cyclophosphamide.
    Transplant Cell Ther· 2025· PMID 41443572recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:890(Orphanet)
  2. MONDO:0019514(MONDO)
  3. GARD:13004(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q5731687(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Doença veno-oclusiva hepática
Compêndio · Raras BR

Doença veno-oclusiva hepática

ORPHA:890 · MONDO:0019514
Prevalência
Unknown
Herança
Not applicable
CID-10
K76.5 · Doença hepática veno-oclusiva
CID-11
Ensaios
3 ativos
Medicamentos
2 registrados
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0019156
EuropePMC
Wikidata
Papers 10a
Evidência
🥇 Meta-análise
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades